Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a serious, long-term illness that dramatically reduces a person’s ability to carry out everyday activities. It affects roughly 1.3% of U.S. adults, and its hallmark feature is a worsening of symptoms after physical, mental, or emotional effort that would have been manageable before the illness began. ME/CFS is not ordinary tiredness, and rest does not resolve it.
Core Symptoms and How It’s Diagnosed
There is no blood test or scan that can confirm ME/CFS. Diagnosis is based on a specific pattern of symptoms, using criteria published in 2015 by the Institute of Medicine (now the National Academy of Medicine). Three symptoms are required, plus at least one of two additional ones.
The required symptoms are:
- Significant reduction in functioning that lasts more than six months, accompanied by fatigue that is new (not lifelong), often profound, not caused by unusual exertion, and not substantially relieved by rest.
- Post-exertional malaise (PEM), a worsening of symptoms after effort that wouldn’t have been a problem before the illness. This can be triggered by something as minor as a short walk or a cognitively demanding conversation, and the flare may not hit until hours or even days later.
- Unrefreshing sleep, meaning a full night of sleep does not leave you feeling rested. This happens even when no specific sleep disorder is present.
In addition, at least one of these must also be present:
- Cognitive impairment, often called “brain fog,” involving problems with memory, concentration, information processing, and executive function.
- Orthostatic intolerance, a worsening of symptoms when standing or sitting upright.
For a diagnosis, these symptoms need to be present at least half the time at a moderate or greater intensity. Doctors also rule out other conditions that could explain the symptoms, such as thyroid disorders or sleep apnea.
What Happens in the Body
ME/CFS is not a psychological condition. Research has identified a range of biological abnormalities, though scientists are still working to piece together exactly how they interact.
One of the clearest findings involves energy production at the cellular level. Immune cells taken from people with ME/CFS show reduced ability to generate energy, both at rest and when activated. Their mitochondria, the structures inside cells responsible for producing energy, function abnormally. CD8+ T cells (a type of immune cell that fights infections) show a measurable drop in energy output after activation compared to healthy cells. This helps explain why even minor exertion can overwhelm the body.
At the same time, the immune system appears to be stuck in a state of chronic low-grade activation. Studies of gene expression in ME/CFS patients show that inflammatory pathways are turned up while metabolic pathways are turned down. Genes involved in the body’s early inflammatory response are significantly more active than in healthy people, suggesting an ongoing biological inflammatory process rather than something imagined or behavioral.
Brain imaging has added another piece to the puzzle. A PET study found that markers of neuroinflammation (activation of the brain’s immune cells) were 45% to 199% higher across multiple brain regions in ME/CFS patients compared to healthy controls. The areas affected included regions involved in memory, emotion, pain processing, and arousal. Importantly, the degree of inflammation in specific brain areas correlated with the severity of particular symptoms: more inflammation in the memory-related hippocampus tracked with worse depression scores, while inflammation in the thalamus tracked with worse cognitive impairment and pain.
Autonomic Nervous System Problems
The autonomic nervous system controls functions you don’t consciously think about: heart rate, blood pressure, digestion, temperature regulation, and sweating. In ME/CFS, this system frequently malfunctions. Between 30% and 70% of patients have some form of orthostatic intolerance, meaning their body struggles to maintain normal circulation when they’re upright. This can cause dizziness, lightheadedness, a racing heart, or the urge to lie down.
In one large study, ME/CFS patients reported dramatically higher rates of autonomic symptoms compared to healthy people: dizziness or vertigo (43% vs. 3%), cold extremities (39% vs. 6%), and orthostatic intolerance (34% vs. less than 1%). These autonomic problems don’t just cause discomfort on their own. They appear to worsen fatigue, sleep disruption, cognitive difficulties, and pain, compounding the overall burden of the illness.
Post-Exertional Malaise: The Defining Feature
PEM is what most clearly separates ME/CFS from other fatiguing conditions. It is not simply feeling tired after doing too much. It is a systemic crash in which multiple symptoms intensify, sometimes severely, following an amount of effort that a healthy person wouldn’t think twice about. A grocery trip, a phone call with a difficult relative, or even a hot shower can trigger it.
The delay is what makes PEM especially tricky. You might feel fine during the activity and only crash 12 to 72 hours later, making it hard to connect cause and effect without careful tracking. A crash can last days or weeks, and repeated overexertion can lead to a permanent worsening of baseline function.
How It’s Managed
There is currently no cure for ME/CFS, and no drug has been approved specifically to treat it. Management focuses on preventing symptom flares, particularly PEM, and improving quality of life within the limits the illness imposes.
The most widely recommended strategy is pacing, which means learning to stay within your available energy rather than pushing through and crashing. The CDC recommends keeping a daily diary for one to two weeks, tracking activities (including type, intensity, and duration) alongside symptoms. Patterns often emerge: you might find that 30 minutes of reading is fine but an hour triggers a crash. That 30-minute mark becomes your “energy envelope” for that activity.
Practical pacing techniques include setting timers to stop activities before hitting your limit, alternating between different types of tasks, scheduling demanding activities for your best time of day, and building in rest before you feel you need it. Some people use heart rate monitors to avoid crossing their anaerobic threshold, the point at which the body shifts to a less efficient form of energy production that can trigger PEM.
In 2021, the UK’s National Institute for Health and Care Excellence (NICE) issued updated guidelines that explicitly stated graded exercise therapy, programs that use fixed incremental increases in physical activity, should not be offered to people with ME/CFS. This was a significant reversal from earlier guidance and reflected growing evidence that pushing patients to progressively increase activity can cause harm. The guidelines also clarified that cognitive behavioral therapy may help some patients manage their symptoms but is not a cure and should not be presented as one.
Who Gets ME/CFS
ME/CFS affects all ages, sexes, and ethnic groups, but the distribution is uneven. Women are roughly twice as likely as men to have it (1.7% vs. 0.9%). Adults living below the federal poverty line have the highest rates at 2.0%, which may reflect the compounding effects of limited access to healthcare, higher stress, or occupational factors. White non-Hispanic adults (1.5%) have higher reported rates than Asian non-Hispanic (0.7%) or Hispanic (0.8%) adults, though this gap may partly reflect differences in diagnosis rates rather than true prevalence.
The illness often begins after an acute viral infection, a pattern that gained wider public attention during the COVID-19 pandemic as many long COVID patients developed symptoms indistinguishable from ME/CFS. The economic toll is substantial: ME/CFS costs the U.S. economy an estimated $18 to $51 billion annually, driven largely by lost productivity. Roughly one-third of patients who were previously in the workforce stop working entirely, and those who continue see their income drop by about a third.
The Search for a Diagnostic Test
One of the biggest challenges facing ME/CFS patients is the lack of a definitive lab test. Diagnosis relies on clinical evaluation, which means many patients wait years, see multiple doctors, and face skepticism before getting an answer. A high priority for the ME/CFS community is an accurate, reliable blood-based diagnostic test.
Researchers have identified promising biological markers. One involves an enzyme called PKR, which is part of the innate immune response to viral infections. In healthy people, the activated form of this enzyme is undetectable in immune cells. In ME/CFS patients, it is consistently present. Other research has found panels of blood traits that differ between patients and healthy controls, even after accounting for the low physical activity levels common in ME/CFS. However, no single marker has been able to cleanly distinguish patients from healthy individuals on its own, and a validated clinical test remains unavailable.